This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Botanix Pharmaceuticals Limited
Drug Names(s): BTX1204, BTX 1204
Description: BTX1204 contains cannabidiol as an active ingredient and can exert potent analgesic effects by activation of CB1 and/or CB2 receptors in the skin and possibly other receptors at sensory nerve terminals and/or inflammatory cells.
Deal Structure: In March 2013, Bone Medical announced it has signed an agreement to acquire Botanix Pharmaceuticals, Inc. In June 2016, Bone Medical announced that the Prospectus Offer for the acquisition of Botanix Pharmaceuticals has closed and a shareholder meeting was held where existing shareholders approved the acquisition of Botanix Pharmaceuticals, including the resolution to change the name of the company to Botanix Pharmaceuticals Limited.
Additional information available to subscribers only: